Viral hepatitis B and hepatocellular carcinoma

Acta Gastro-Enterologica Belgica

Volumn 74, Issue 1, 2011, Pages 4-8

  Michielsen, P ^a   Ho, E ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hepatitis B; Hepatocellular carcinoma; Interferon; Natural history; Nucleos(t)ide analogues

Indexed keywords

AFLATOXIN B1; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA; PLACEBO; TENOFOVIR; VIRUS DNA;

AGE; ALCOHOL CONSUMPTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASIAN; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CAUCASIAN; COMORBIDITY; DIABETES MELLITUS; DNA INTEGRATION; DNA REPAIR; EUROPE; GENDER; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; KOREA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; OBESITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TAIWAN; UNITED STATES; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 79956271546     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. PARKIN D.M., BRAY F., FERLAY J., PISANI P. Global Cancer Statistics, 2002. CA Cancer J. Clin., 2005, 55: 74-108.
2. LLOVET J.M., BURROUGHS A., BRUIX J. Hepatocellular carcinoma. Lancet, 2003, 362: 1907-1917.
3. BLUMBERG B.S., LAROUZÉ B., LONDON W.T., WERNER B., HESSER J.E., MILLMAN I., SAIMOT G., PAYET M. The relation of infection with the hepatitis B agent to primary hepatic carcinoma. Am. J. Pathol., 1975, 81: 669-682.
4. KEW M.C. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol. Biol. (Paris), 2010, 58: 273-277.
5. CHEN C.L., YANG H.I., YANG W.S., LIU C.J., CHEN P.J., YOU S.L., WANG L.Y., SUN C.A., LU S.N., CHEN D.S., CHEN C.J. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology, 2008, 135: 111-121.
6. BEASLEY R.P., HWANG L.-Y. Epidemiology of hepatocellular carcinoma. In: VYAS G.N. (ed). DIENSTAG J.L., HOOFNAGLE J.H. Viral hepatitis and Liver Disease. Orlando, FL: Guine & Stratton, 1984: 209-244.
7. KEW MC., DESMYTER J., BRADBURNE AF., MACNAB GM. Hepatitis B virus infection in southern African blacks with hepatocellular cancer. J. Natl. Cancer Inst., 1979, 62: 517-520.
8. SHERMAN M., PELTEKIAN KM., LEE C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology, 1995, 22: 432-438.
9. FATTOVICH G., BORTOLOTTI F., DONATO F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol., 2008, 48: 335-352.
10. DONATO F., TAGGER A., GELATTI U., PARRINELLO G., BOFFETTA P., ALBERTINI A., DECARLI A., TREVISI P., RIBERO ML., MARTELLI C., PORRU S., NARDI G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol., 2002, 155: 323-331.
11. CHEN C.L., YANG H.I., YANG W.S., LIU C.J., CHEN P.J., YOU S.L., WANG L.Y., SUN C.A., LU S.N., CHEN D.S., CHEN C.J. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology, 2008, 135: 111-121.
12. KEW M.C. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int., 2003, 23: 405-409.
13. CHEN C.J., YANG H.I., SU J., JEN C.L., YOU S.L., LU S.N., HUANG G.T., ILOEJE U.H.; REVEAL-HBV STUDY GROUP. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, 295: 65-73.
14. MENDY M.E., WELZEL T., LESI O.A., HAINAUT P., HALL A.J., KUNIHOLM M.H., MC CONKEY S., GOEDERT J.J., KAYE S., ROWLAND-JONES S., WHITTLE H., KIRK G.D. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J. Viral. Hepat., 2010, 17: 115-122.
15. YU M.W., YEH S.H., CHEN P.J., LIAW Y.F., LIN C.L., LIU C.J., SHIH W.L., KAO J.H., CHEN D.S., CHEN C.J. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl. Cancer Inst., 2005, 97: 265-272.
16. DONATO F., BOFFETTA P., PUOTI M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer, 1998, 75: 347-354.
17. SHI J., ZHU L., LIU S., XIE WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br. J. Cancer, 2005, 92: 607-612.
18. PARK N.H., SONG I.H., CHUNG Y.H. Chronic hepatitis B in hepatocarcinogenesis. Postgrad. Med. J., 2006, 82: 507-515.
19. KREMSDORF D., SOUSSAN P., PATERLINI-BRECHOT P., BRECHOT C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viralrelated human carcinogenesis. Oncogene, 2006, 25: 3823-3833.
20. KOSHY R., MAUPAS P., MÜLLER R., HOFSCHNEIDER P.H. Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues. J. Gen. Virol., 1981, 57 (Pt 1): 95-102.
21. BECKER S.A., LEE T.H., BUTEL J.S., SLAGLE B.L. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol., 1998, 72: 266-272.
22. TAKADA S., KANENIWA N., TSUCHIDA N., KOIKE K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene, 1997, 15: 1895-1901.
23. KEKULÉ A.S., LAUER U., WEISS L., LUBER B., HOFSCHNEIDER P.H. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature, 1993, 361: 742-745.
24. BRUIX J., SHERMAN M.; PRACTICE GUIDELINES COMMITTEE, AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES. Management of hepatocellular carcinoma. Hepatology, 2005, 42: 1208-1236 (update July, 2010).
25. CHEN D.S. Hepatocellular carcinoma in Taiwan. Hepatol. Res., 2007 Sep, 37 Suppl 2: S101-105.
26. CHANG M.H., CHEN C.J., LAI M.S., HSU H.M., WU T.C., KONG M.S., LIANG D.C., SHAU W.Y., CHEN D.S.; THE TAIWAN CHILDHOOD HEPATOMA STUDY GROUP. Universal Hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med., 1997, 336: 1855-1859.
27. CHANG M.H., CHEN T.H.H., HSU H.M., WU T.C., KONG M.S., LIANG D.C., NI Y.H., CHEN C.J., CHEN D.S. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin. Cancer Res., 2005, 11: 7953-7957.
28. CHANG M.H., YOU S.L., CHEN C.J., LIU C.J., LEE C.M., LIN S.M., CHU H.C., WU T.C., YANG S.S., KUO H.S., CHEN D.S.; THE TAIWAN HEPATOMA STUDY GROUP. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl. Cancer Inst., 2009, 101: 1348-1355.
29. LEE M.S., KIM D.H., KIM H., LEE H.S., KIM C.Y., PARK T.S., YOO K.Y., PARK B.J., AHN Y.O. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int. J. Epidemiol., 1998, 27: 316-319.
30. COLLE I., ADLER M., BRENARD R., HENRION J., LANGLET P., MICHIELSEN P., ORLENT H., REYNAERT H., SPRENGERS D., STÄRKEL P., VAN DAMME P., VERSLYPE C., DELWAIDE J.; BELGIAN ASSOCIATION FOR THE STUDY OF THE LIVER. Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL), 2007 guidelines. Acta Gastroenterol. Belg., 2007, 70: 389-420.
31. LIN S.M., SHEEN I.S., CHIEN R.N., CHU C.M., LIAW Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology, 1999, 29: 971-975.
32. VAN ZONNEVELD M., HONKOOP P., HANSEN B.E., NIESTERS H.G., DARWISH MURAD S., DE MAN R.A., SCHALM S.W., JANSSEN H.L. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology, 2004, 39: 804-810.
33. LIN S.M., TAI D.I., CHIEN R.M., SHEEN I.S., CHU C.M., LIAW Y.F. Comparison of long-term effects of lymphoblastoid interferon alpha and recombination interferon alpha and recombinant interferon alpha 2a therapy in patients with chronic hepatitis B. J. Viral. Hepat., 2004, 11: 349-357.
34. YUEN M.F., HUI C.K., CHENG C.C., WU C.H., LAI Y.P., LAI C.L. Longterm follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology, 2001, 34: 139-145.
35. PAPATHEODORIDIS G.V., PETRAKI K., CHOLONGITAS E., KANTA E., KETIKOGLOU I., MANESIS E.K. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J. Viral Hepat., 2005, 12: 199-206. Erratum in: J. Viral Hepat., 2005, 12:443.
36. LAMPERTICO P., DEL NINNO E., VIGANÒ M., ROMEO R., DONATO M.F., SABLON E., MORABITO A., COLOMBO M. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology, 2003, 37: 756-763.
37. OON C.J. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk precancerous conditions. Cancer Chemother. Pharmacol., 1992, 31 (Suppl): 137-142.
38. MAZZELLA G., ACCOGLI E., SOTTILI S., FESTI D., ORSINI M., SALZETTA A., NOVELLI V., CIPOLLA A., FABBRI C., PEZZOLI A., RODA E. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol., 1996, 24: 141-147.
39. FATTOVICH G., GIUSTINA G., REALDI G., CORROCHER R., SCHALM S.W. Longterm outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology, 1997, 26: 1338-1342.
40. IKEDA K., SAITOH S., SUZUKI Y., KOBAYASHI M., TSUBOTA A., FUKUDA M., KOIDA I., ARASE Y., CHAYAMA K., MURASHIMA N., KUMADA H. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer, 1998, 82: 827-835.
41. INTERNATIONAL INTERFERON-ALPHA HEPATOCELLULAR CARCINOMA STUDY GROUP. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet, 1998, 351: 1535-1539.
42. BENVEGNÙ L., CHEMELLO L., NOVENTA F., FATTOVICH G., PONTISSO P., ALBERTI A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer, 1998, 83: 901-909.
43. DI MARCO V., LO IACONO O., CAMMA C., VACCARO A., GIUNTA M., MARTORANA G., FUSCHI P., ALMASIO P.L., CRAXI A. The long-term course of chronic hepatitis B. Hepatology, 1999, 30: 257-264.
44. CAMMA C., GIUNTA M., ANDREONE P., CRAXI A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol., 2001, 34: 593-602.
45. LIAW Y.F., SUNG J.J., CHOW W.C., FARRELL G., LEE C.Z., YUEN H., TANWANDEE T., TAO Q.M., SHUE K., KEENE O.N., DIXON J.S., GRAY D.F., SABBAT J.; CIRRHOSIS ASIAN LAMIVUDINE MULTICENTRE STUDY GROUP. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med., 2004, 351: 1521-1531.
46. DI MARCO V., MARZANO A., LAMPERTICO P., ANDREONE P., SANTANTONIO T., ALMASIO PL., RIZZETTO M., CRAXÌ A.; ITALIAN ASSOCIATION FOR THE STUDY OF THE LIVER (AISF) LAMIVUDINE STUDY GROUP, ITALY. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology, 2004, 40: 883-891.
47. PAPATHEODORIDIS G.V., LAMPERTICO P., MANOLAKOPOULOS S., LOK A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol., 2010, 53: 348-356. Gastroenterology, 2000, 119: 431-440.
48. POON R.T., FAN S.T., NG I.O., LO C.M., LIU C.L., WONG J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer, 2000, 89: 500-507.
49. WU J.C., HUANG Y.H., CHAU G.Y., SU C.W., LAI C.R., LEE P.C., HUO T.I., SHEEN I.J., LEE S.D., LUI W.Y. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J. Hepatol., 2009, 51: 890-897.
50. QU L.S., JIN F., HUANG X.W., SHEN X.Z. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J. Gastrointest. Surg., 2010, 14: 1111-1120.
51. HUNG I.F., POON R.T., LAI C.L., FUNG J., FAN S.T., YUEN M.F. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am. J. Gastroenterol., 2008, 103: 1663-1673.
52. MIAO R.Y., ZHAO H.T., YANG H.Y., MAO Y.L., LU X., ZHAO Y., LIU C.N., ZHONG S.X., SANG X.T., HUANG J.F. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol., 2010, 16: 2931-2942.
53. ZIMMERMAN M.A., GHOBRIAL R.M., TONG M.J., HIATT J.R., CAMERON A.M., BUSUTTIL R.W. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant. Proc., 2007, 39: 3276-3280.
54. FARIA L.C., GIGOU M., ROQUE-AFONSO A.M., SEBAGH M., ROCHE B., FALLOT G., FERRARI T.C., GUETTIER C., DUSSAIX E., CASTAING D., BRECHOT C., SAMUEL D. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology, 2008, 134: 1890-9; quiz 2155.